601
Participants
Start Date
January 22, 2016
Primary Completion Date
March 7, 2018
Study Completion Date
March 7, 2018
Infanrix hexa
• All subjects will receive Infanrix hexa at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. Infanrix hexa is administered intramuscularly to the right thigh.
Prevnar13
• All subjects will receive Infanrix hexa co-administered with Prevenar13\* at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. \*In some countries/regions with an Infanrix hexa 3-dose vaccination schedule, Prevenar 13 could be administered as 2-doses or 3-doses primary vaccination schedule (according to the routine national immunisation schedule). Prevnar13 is administered intramuscularly to the left thigh.
GSK Investigational Site, Carlton
GSK Investigational Site, Turin
GSK Investigational Site, Prague
GSK Investigational Site, Santiago de Compostela
GSK Investigational Site, Milan
GSK Investigational Site, Milan
GSK Investigational Site, Milan
GSK Investigational Site, Turku
GSK Investigational Site, Aravaca
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Novara
GSK Investigational Site, Majadahonda (Madrid)
GSK Investigational Site, Móstoles
GSK Investigational Site, Málaga
GSK Investigational Site, Antequera/Málaga
GSK Investigational Site, Tampere
GSK Investigational Site, Seville
GSK Investigational Site, Seinäjoki
GSK Investigational Site, Kokkola
GSK Investigational Site, Oulu
GSK Investigational Site, Calgary
GSK Investigational Site, Halifax
GSK Investigational Site, Montreal
GSK Investigational Site, Brno
GSK Investigational Site, Hradec Králové
GSK Investigational Site, Ostrava - Vitkovice
GSK Investigational Site, Prague
GSK Investigational Site, Burgos
Lead Sponsor
GlaxoSmithKline
INDUSTRY